• Gallant raises $18 million in Series B financing, led by Digitalis Ventures, to advance the first ready-to-use stem cell therapy through conditional FDA approval.
• NovaQuest joins as a new investor, bringing deep experience from the first human FDA-approved allogeneic stem cell therapy, to support Gallant’s leadership in veterinary regenerative medicine.
• Continued significant support from BOLD Capital and Hill Creek Partners, further validating Gallant’s potential by sophisticated investors and animal health industry insiders.

SAN DIEGO, June 30, 2025 — Gallant, an animal health biotechnology company pioneering off-the-shelf stem cell therapies for pets, announced the successful closing of its $18 million Series B financing. The round was led by Digitalis Ventures, with continued support from BOLD Capital and Hill Creek Partners, and new participation from NovaQuest Capital Management.

Gallant is creating a new category in veterinary care with ready-to-use stem cell therapies that target the root cause of the most common and underserved diseases in dogs and cats. Its first product for refractory Feline Chronic Gingivostomatitis (FCGS) is on track for FDA conditional approval in early 2026, and could become the first FDA-labeled, allogeneic stem cell therapy in veterinary medicine.

With this funding, Gallant accelerates its path to initial commercial rollout of its lead product for FCGS, while advancing a pipeline of therapies for Canine and Feline Osteoarthritis (COA and FOA), Canine Atopic Dermatitis (CAD), and Feline Chronic Kidney Disease (CKD) – conditions where current standards of care manage symptoms rather than address the underlying disease.

“We have been continually impressed by Gallant’s team, clarity of vision, and ability to deliver. They’re tackling some of the most persistent needs in animal health using their proprietary technology platform to bring truly differentiated solutions to veterinarians and pets in need – meaningful innovation that targets the disease, not just symptoms,” said Dr. Cindy Cole, Technical Partner at Digitalis Ventures.

“Gallant has made significant strides in a short time, advancing a new class of therapies grounded in science and built for scale,” said Teymour Boutros-Ghali, Managing Partner at BOLD Capital. “As it moves through FDA review toward commercialization, we’re excited to stand behind a team pushing the boundaries of what’s possible in veterinary care.”

NovaQuest Capital Management’s participation brings notable category experience with their investment in Mesoblast. Their first product, RYONCIL^®, became the first-ever FDA-approved human allogeneic mesenchymal stromal cell (MSC) therapy in the U.S. in December 2024.

“Regenerative medicine is entering its prime – we’ve seen it firsthand with the success of allogeneic stem cell therapies in human healthcare,” said Brian Axe, Partner at NovaQuest. “Gallant is bringing that same caliber of science to animal health with off-the-shelf therapies for pets targeting the root cause of disease where current care falls short. We’re thrilled to help bring these pioneering therapies to market.”

Gallant’s research, focused on canine and feline osteoarthritis, feline chronic kidney disease, and feline chronic gingivostomatitis, found that only 56% of veterinarians are satisfied with treatments for canine OA – and just 8% for FCGS. Most veterinarians understand that current therapies manage symptoms, not the underlying disease, and roughly half of veterinarians express a strong interest in using regenerative medicine across conditions. Gallant’s therapies are designed to meet that demand: ready-to-use, science-backed, and developed under FDA oversight.

“We’re honored to have the backing of partners who share our vision in creating this new category of medicine that doesn’t just help pets feel better, but helps pets get better,” said Dr. Linda Black, CEO of Gallant. “The FDA approval of the first human allogeneic stem cell therapy was a historic milestone, and we’re looking forward to delivering this breakthrough therapy for animal health.”

Gallant’s proprietary stem cell platform harnesses the unique potential of uterine-derived mesenchymal stem cells. The anticipated conditional approval of the FCGS therapy would offer new hope to cats facing this debilitating disease and help lay the regulatory roadmap for future off-the-shelf stem cell therapies. This work is part of Gallant’s larger mission: to make stem cell therapy accessible to every pet who needs it.

About Gallant

Gallant is an animal health biotechnology company creating a new category of veterinary medicine with a pipeline of off-the-shelf stem cell therapies targeting the root causes of diseases in pets. Led by pioneers in veterinary regenerative medicine with deep expertise in development, manufacturing, and commercialization, Gallant is making regenerative medicine accessible – moving beyond symptom management to restoring health at the source. Learn more at https://www.gallant.com/.

About Digitalis Ventures
Digitalis Ventures backs founders solving critical problems in health. The firm invests in early-stage companies across the healthcare ecosystem with the goal of supporting them through multiple rounds of financing. Digitalis is headquartered in New York City. Learn more at https://www.digitalisventures.com/.

About BOLD Capital
BOLD Capital is a venture capital firm focused on partnering with entrepreneurs and companies that share a bold vision for a brighter future. The firm invests primarily in two transformative areas: health and life sciences, and deep tech and productivity. BOLD identifies emerging science and technologies with the potential to disrupt and democratize massive markets, creating innovative solutions to some of humanity’s most pressing challenges. The firm is headquartered in Santa Monica, California. Learn more at https://boldcapitalpartners.com/.

About NovaQuest Capital Management
NovaQuest Capital Management, located in North Carolina’s Research Triangle, is a life science investment firm with a specialization in biopharmaceuticals. Founded in 2010, and with more than $2.5 billion raised across multiple funds, NovaQuest provides tailored capital solutions that fund innovation in biopharmaceutical development and invests in compelling healthcare companies with products and technologies aimed at helping humans and animals live healthier, longer, more productive lives. Learn more at https://www.novaquest.com/.

Contact:
Galyna Danylenko
+1 (443) 254-7567
[email protected]

SOURCE Gallant

Alexandros Petkos awarded $100K to develop open-source general-purpose robots for hazardous and repetitive tasks 

GREENWICH, Conn., June 30, 2025 — O’Shaughnessy Ventures LLC (OSV), an investment firm that empowers creators, has awarded a $100,000 O’Shaughnessy Fellowship to Alexandros Petkos, a robotics engineer based in Athens, Greece.

Petkos will use the fellowship to build open-source, general-purpose autonomous robots capable of performing hazardous or repetitive tasks, potentially addressing labor shortages across multiple industries. To achieve this, he will gather extensive robotics data to train advanced AI models, which he will integrate into the robots.

Petkos brings extensive robotics experience to the fellowship. At age 20, he built the hardware and software for a robot capable of physical tasks such as lifting and placing cardboard boxes. He fabricated most of the robot’s parts, assembled it himself, and collected datasets to train the AI model powering it. Earlier, at age 17, he built a four-legged robot capable of walking and navigating. This achievement earned him recognition in Forbes Greece’s ’30 Under 30′ list in 2022. Petkos was also a lead engineer at PNOĒ Inc., a Y Combinator-backed health technology startup.

OSV’s founder and CEO, Jim O’Shaughnessy, commented, “The fact that Alexandros has already built two functioning robots speaks volumes. We’re here to give him the support he needs to take his work to the next level.”

“Surrounding yourself with driven, ambitious people is essential for making real progress,” said Petkos. “I’m truly grateful to the OSV team for the opportunity to learn from and be inspired by the exceptional individuals in this community.”

About the O’Shaughnessy Fellowships Program

Launched in 2023, the O’Shaughnessy Fellowships program discovers and empowers the world’s boldest creatives, builders and researchers. Fellows receive a $100,000 grant and gain access to OSV’s network of founders, investors and experts.

OSV will award 12 fellowships in 2025. Applicants will also be considered for the O’Shaughnessy Grants program, which provides 20 additional $10,000 grants to promising innovators.

Petkos is the eleventh fellow announced in 2025. More information about previous fellows is available at OSV’s website.

Applications for the fellowships are now closed and will reopen on Jan. 1, 2026. Individuals interested in learning more can do so via OSV’s website.

About O’Shaughnessy Ventures

OSV is a creative investment firm that empowers creators to bring their ideas to life. Founded by Jim O’Shaughnessy, a pioneer in quantitative investing, founder of O’Shaughnessy Asset Management, and author of five books, OSV aims to provide financial support and to partner in growing the next life-changing creative ideas.

OSV combines Jim’s deeply rooted interest in all things art, science, investing and technology with his long-held desire to establish scenarios designed to help promising creators and their inspiring ideas succeed, regardless of age, location, job history or level of education. For more information, visit OSV’s website.

Media Contact:
Ena Gong
O’Shaughnessy Ventures LLC
(917) 355-7420
[email protected]

SOURCE O’Shaughnessy Ventures

MECHANICSBURG, Pa. and NEW DELHI, June 30, 2025 — Emerge Education, a leading U.S.-based provider of enrollment, marketing, and international education services, has formed a strategic partnership with Shiftzzy, a smart student integration and support platform, to enhance the experience of international students coming to the United States.

Through this collaboration, universities and student service providers can now offer Shiftzzy’s all-in-one app to streamline key transition points such as housing, community-building, mentorship, student visas, education loans, and ongoing support. The partnership helps institutions meet student needs more efficiently—ultimately improving satisfaction and retention outcomes.

Shiftzzy is available globally on iOS and Android and is designed to support the full student lifecycle—from pre-arrival and orientation through graduation and beyond. The platform connects incoming, current, short-term, and alumni students, reducing the institutional workload typically managed by housing offices, orientation teams, International Student and Scholar Services (ISSS), student life departments, and career services.

“Universities are under increasing pressure to support international students with limited resources,” said James M. Hunter, PhD, CEO of Emerge Education. “Our partnership with Shiftzzy introduces a technology solution designed to help institutions deliver more effective support while focusing their efforts on improving engagement and long-term student success.”

Addressing a Critical Market Demand

Research indicates that while international students prefer digital support tools, they often find existing platforms fragmented or insufficient. In a 2024 survey of U.S. international students, 33% reported experiencing social and academic challenges—such as homesickness and difficulty making friends—and 29% expressed a need for more support in those areas. These findings underscore the importance of platforms like Shiftzzy, which provide centralized housing guidance, peer networking, mentorship, and administrative support to help students feel welcomed, connected, and set up for success.

Shiftzzy aims to address these challenges through the following features:

• Smart Roommate Matching, using unique filters to reduce conflict and housing stress
• Personalized Housing Concierge Services, assisting with leases, budgeting, and relocation
• Mentorship and Career Support, including job search guidance, mental health resources, visa advising, and alumni networking
• Global Peer Networking prior to arrival, to build belonging and early engagement
• Student Saver Deals offering discounts on essentials like banking, mobile plans, and local services

“Shiftzzy was created to simplify the study-abroad journey through accessible and scalable support,” said Adarsh Kakarania, Shiftzzy co-founder. “This partnership with Emerge allows us to extend that support to institutions that are seeking more efficient, student-centered integration tools.”

“Students face considerable uncertainty when moving abroad,” added Tanya Wadhwa Kakarania, co-founder of Shiftzzy. “Our platform helps ease that transition by offering centralized access to the resources and connections they need—while reducing the institutional workload.”

Proven Results with Scalable Impact

Shiftzzy already serves over 500 active users in just five months, has formalized a partnership with SUNY Oswego, and is currently in discussions with several other universities. They were also selected for the prestigious Startup Nexus program by the U.S. Embassy in India and the University of Connecticut.

With Emerge’s expertise in recruitment, marketing, and international enrollment, the platform is well-positioned to help institutions respond to digital engagement expectations while improving integration, retention, and student well-being.

To explore a university partnership or request a Shiftzzy demo, visit Shiftzzy.com or download the app today.

About Emerge Education

Emerge Education is one of the nation’s leading higher education services companies, dedicated to delivering strategic enrollment, marketing, and consulting solutions. Through its international division, Emerge supports institutions in maximizing enrollment, enhancing global brand recognition, and launching new academic pathways. Learn more at emergeedu.com.

About Shiftzzy

Shiftzzy is a dynamic student experience platform designed to simplify the study-abroad journey and strengthen campus integration. With features spanning recruitment, housing, community-building, mentorship, and student savings, Shiftzzy empowers international students while supporting universities and service providers in achieving retention, satisfaction, and engagement goals. Visit shiftzzy.com for more information.

Media Contact:
Christopher Wilford
Senior Vice President of Marketing
Emerge Education
Phone: 717-214-1631
Email: [email protected]

SOURCE Emerge Education

• Fund II advances Recognize’s strategy of accelerating the growth of next-generation Digital Services companies seeking to deliver transformative solutions
• Strong participation from existing LPs and significant demand from new blue-chip investors
• Oversubscribed fund reached its hard cap in under five months

NEW YORK, June 30, 2025 — Recognize, a proven investor in and builder of next-generation Digital Services companies, today announced the final close of its second fund, Recognize Partners II/II-A, L.P. (“Recognize II”), with over $1.7 billion in total commitments. Co-founded by Managing Partners Francisco D’Souza, Charles Phillips, and David Wasserman, Recognize has quickly established itself as a notable investor-operator and trusted partner to digital services innovators.

Recognize seeks to back visionary founders and management teams who are building differentiated businesses that leverage AI, software, and digital platforms to deliver transformative outcomes to enterprises. With Recognize II, the firm continues to focus on investing in companies with enterprise values between approximately $50 million and $500 million – businesses that Recognize believes offer strong potential for accelerated growth with the support of Recognize’s partnership-driven value creation approach.

Recognize II was oversubscribed and closed less than five months from launch, with strong support from existing investors, including a significant GP commitment, and a curated group of new investors. The LP base includes leading global institutions such as endowments, foundations, pensions, insurers, family offices, outsourced CIOs and fund-of-funds across the U.S., Europe, Asia, and Latin America.

Over the last six months, Recognize has made four new platform investments: SDG Corporation (cybersecurity services), Sprout (Digital Infrastructure Services), TRANZACT (insurance services), and HealthEdge (SaaS for healthcare payers).

The firm also completed two realization events earlier this year: the exit of AST, sold to IBM, and a partial exit of 2X through a strategic investment by Insight Partners. In 2024, Recognize also sold Torc, an AI-powered talent platform, to a subsidiary of Randstad. These realizations, in Recognize’s view, further reinforce the firm’s thesis that next-generation Digital Services firms are increasingly attractive to strategic buyers.

“We are incredibly grateful for the continued support of our partners,” said Debbie Park Munfa, Partner and Head of Investor Relations at Recognize. “We remain focused on building Digital Services businesses for the future and partnering with excellent management teams to deliver long-term value for our investors.”

Recognize was advised on the fundraise by Rede Partners Americas LLC, with Goodwin Procter LLP serving as legal and tax counsel.

About Recognize

Recognize is a distinguished investor and business builder focused on next-generation Digital Services companies. Headquartered in New York, the firm seeks to back visionary founders, entrepreneurs, and management teams who are building innovative businesses that leverage AI, software, and digital platforms to deliver transformative outcomes to enterprises. Recognize provides deep operational expertise, industry relationships, and strategic capital to drive accelerated growth of these specialized businesses. To learn more, visit www.recognize.com. 

Contact
Debbie Park Munfa
Recognize
[email protected]

SOURCE Recognize

MIAMI LAKES, Fla., June 30, 2025 — USpharma Ltd., a pharmaceutical development and manufacturing company commercializing several novel delivery platforms, today announced a significant growth equity investment by 1315 Capital, a Philadelphia-based healthcare growth equity firm.

USpharma leverages advanced and patented formulation technologies, including its next generation soft chewable dosage forms and the unique capabilities of its 150,000 square foot US-based GMP facility, to develop and manufacture innovative products across multiple pharmaceutical and supplement markets. This capital infusion will enable USpharma to accelerate the development and commercialization of its pipeline and scale operations to meet growing market demand.

“We are thrilled to partner with 1315 Capital as we enter this pivotal stage of growth,” said Manesh Dixit, Ph.D., Chief Executive Officer of USpharma Ltd. “This investment allows us to advance our mission to deliver science-backed, high-quality health solutions that improve patient access and adherence. We’re excited to bring our next-generation products to a broader audience with the support of such an experienced partner.”

“Consumers are increasingly focused on health and wellness solutions that are not only efficacious but delivered in a format that fits with their preferences and lifestyle.” said Matthew Reber, Partner at 1315 Capital. “We are proud to partner with USpharma as they expand their commercial reach and provide compelling product formulations in numerous large and growing healthcare markets,”

About USpharma Ltd.
USpharma Ltd. is a privately held healthcare company focused on the innovation, development, licensing, and commercialization of healthcare products. Driven by science and patient need, USpharma delivers accessible, high-quality solutions that improve health and wellness. For more information, please visit www.uspharmaltd.com.

About 1315 Capital
1315 Capital is a private investment firm with over $1 billion of assets under management that provides growth capital to commercial-stage healthcare services, pharmaceutical & medtech outsourced services, pharmaceutical & medtech products, and health & wellness companies. 1315 Capital targets both minority and majority investments in companies where high-quality management teams can rapidly scale platform companies into large and important businesses that positively impact patients, physicians, and the broader healthcare system. For more information, please visit www.1315capital.com.

SOURCE USpharma Ltd.

Backing From Sterling Select to Fuel Electrolyte Boost’s Strategic Growth Across Sports, Health, and Consumer Markets

LOS ANGELES, June 30, 2025 — Electrolyte Boost, a leader in innovative hydration and electrolyte support products, today announced the closing of a venture development deal with Sterling Select Group LLC (“Sterling Select”), and a simultaneous closing of its seed round from Sterling Select’s partners.

“Electrolyte Boost’s ground-breaking waterless electrolyte replenishment and functional nutrition solutions are not just category-defining, they fit perfectly across many market segments where the consumer seeks both physical and mental performance, as well as incredible recovery.  We have already tested the products with athletes of all ages and levels, military and first responders, as well as the medical profession, where carrying bulky liquid containers is just not feasible.  The response has been overwhelmingly positive,” said Christopher J. Steele, Managing Partner at Sterling Select and former NCAA Division I swimmer at Cornell University. 

Sterling Select operates at the intersection of capital and capability, offering early-stage companies like Electrolyte Boost a venture development approach that goes beyond funding to provide a full-service platform for market traction, brand development, and long-term success.

The partnership enables Electrolyte Boost to expand its retail and direct-to-consumer footprint, pursue high-impact partnerships, and further introduce its clinically proven waterless electrolyte replenishment products into performance-focused markets, including in sports, gaming, healthcare and the defense industry.

“Partnering with Sterling Select helps us unlock and ‘boost’ incredible equity value with their operational involvement and corporate development.  Sterling Select’s powerful network, including corporate, strategic and capital partners, will also propel our growth and amplify our impact,” explained Gary Kleinman, Founder and CEO of Electrolyte Boost. “This closing marks the beginning of a broader initiative to accelerate Electrolyte Boost’s growth through corporate development expertise, financial backing, and deep industry relationships across sports, media, healthcare, entertainment, and technology.”

About Electrolyte Boost
Electrolyte Boost, founded by Gary Kleinman, is a doctor-formulated powder that supports performance and hydration without the need for water. By eliminating water as the primary delivery mechanism, Electrolyte Boost offers a simple, fast, and great-tasting way to support overall hydration and activity. Focused on quality and customer satisfaction, Electrolyte Boost provides innovative health and wellness solutions for a variety of lifestyles and activities. For more information, visit www.electrolyteboost.com.

About Sterling Select Group LLC
Sterling Select is a venture development platform associated with Sterling Equities and is focused on early-stage and growth companies. With strategic reach across real estate, sports, entertainment, media, technology, and financial services, Sterling Select partners with entrepreneurs on the one hand, and established companies, organizations and family offices on the other to accelerate growth and create value through strategic capital, ecosystem access, and operating expertise. For more, visit www.sterlingequities.com/ventures

SOURCE Electrolyte Boost

CRED blends business systems, predictive intelligence, and real-world signals to generate contextual insights that drive revenue and operational efficiency.

SAN FRANCISCO, June 30, 2025 — CRED, the AI-powered predictive intelligence platform, today announced it has raised a $15 million seed round led by defy.vc with participation from HOF Capital, Alumni Ventures, LDV Partners, Streamlined Ventures, SilverCircle Ventures, Octopus Ventures, BAM Ventures, Gaingels, alongside the leader of one of the largest PE firms. The company exits stealth with a bold mission: to give every business the predictive advantage once reserved for hedge funds, and turning fragmented systems and signals into intelligent actions, at scale.

CRED transforms how companies harness their data, unifying internal systems with real-time market signals and predictive AI models to deliver intelligent, ranked recommendations & actions tailored to each use case. CRED tells organizations what to do, when to act, and why it matters, turning fragmented data into ranked, contextual insights and automated actions across the tools organizations already use.

Why Now: A Tipping Point for Predictive Intelligence
For years, only hedge funds could afford to build and act on predictive models at scale. Today, that edge is becoming mainstream. Exploding datasets, cheaper compute, and rapid advances in LLMs are making real-time predictions accessible to every enterprise, not just the elite few.

How CRED Works: The Intelligence Layer for Predictive Growth
CRED connects your internal systems with real-time external signals to power smarter execution at scale. The platform turns raw inputs into ranked, contextual insights that help teams focus on what matters most.

• Enrichment & Reporting: Gain full visibility into your data ecosystem by connecting CRM, MAP, and other go-to-market systems. CRED audits data quality in real-time, identifying missing fields, outdated records, and inconsistencies across the entire stack. With access to over 200M+ companies and 900M+ contacts, it enriches records with live market signals like funding events, digital ad spend, hiring trends, and executive moves. This unified layer of enrichment and reporting surfaces insights across macro trends, internal operational efficiency, and the competitive landscape, giving teams the context they need to drive more intelligent execution.
• Intelligent Scoring & Prioritization: Customizable scoring models assess ideal customer profile fit, propensity to churn, and upsell potential to surface high-impact opportunities on an ongoing basis. Real-time alerts notify GTM teams when prospects exhibit buying signals, while synthetic data modeling generates lookalike accounts based on historical wins for more effective targeting.
• Smart Action & Execution: CRED empowers GTM teams to take immediate, intelligent action on enriched data and predictive insights. The platform connects to your existing systems—and includes a built-in outreach tool—so teams can email prospects directly, trigger follow-ups, and launch campaigns without needing to switch tools. CRED automatically builds dynamic account lists, delivers real-time alerts when high-fit accounts show intent, and prioritizes them for engagement. From assigning leads to automating outbound workflows, CRED helps teams move faster, engage smarter, and capitalize on every opportunity.

CRED transforms fragmented data into action-ready intelligence, helping go-to-market teams move faster, prioritize better, and drive revenue with precision.

“We’re in the age of AI where contextual data can now lead to profound business outcomes,” said Jon Carr-Harris, Founder and CEO of CRED. “Just like in science fiction, we can finally start to predict the future. We’re thrilled to prepare the company for its next chapter of growth and grateful for all the support we’ve had from Neil Sequeira at Defy and our incredible group of investors and customers.”

Carr-Harris, a serial entrepreneur with multiple exits and a decade of leadership in AI products, leads a team focused on removing the overhead of managing complex data infrastructures while unlocking new value. CRED doesn’t just analyze existing data—it generates petabytes of proprietary, net-new insights each month, contextualized for every customer. Its predictive intelligence engine has already driven over $100 million in revenue for users in the past year alone, along with over $20 million in cost savings. CRED delivers personalized recommendations for key actions, including real-time scorecards that help sales, marketing, and operations teams identify and prioritize opportunities, optimize spend, and streamline workflows.

“CRED is reimagining enterprise intelligence by combining real-time data, AI, and workflows into a single action-oriented, revenue-driving platform,” said Neil Sequeira, Founder and Partner at defy.vc. “We are excited to back an experienced technical founder like Jon with an incredible AI native team that is deep into customer traction and exponential growth by building an AI operating system for the future of all enterprises.”

Customer Momentum & Market Expansion
While in stealth mode, CRED quietly signed 25 large enterprise customers, including major organizations such as the Golden State Warriors, UTA, and the PGA, saving companies over 10,000 hours of manual data entry per month and driving double-digit revenue growth month over month. CRED will use the funding to scale operations beyond its first vertical in Sports & Entertainment into additional enterprise sectors.

Growth, Hiring & What’s Next
CRED will invest in product development, data models, and expand its go-to-market team. The company has recently opened a new office in San Francisco and is actively hiring across data, sales, engineering, product, and customer success teams.

As AI and large language models (LLMs) capabilities evolve, so does the demand for context-rich intelligence. CRED is uniquely positioned to meet that demand, bridging the gap between signal and strategy, insight and execution.

To learn more, visitcredplatform.com.

About CRED
CRED provides predictive intelligence software that enables enterprises to make data-driven decisions by integrating internal business systems with real-time external market signals. Our platform combines real-time data on over 200 million companies with predictive models to help businesses identify which prospects are likely to convert, which customers are at risk of churning, and when competitors are vulnerable.

About defy.vc
Founded in 2016, defy.vc is a Silicon Valley based early stage venture capital firm. Defy was founded to invest in entrepreneurs and companies looking to solve complex problems. Defy’s focus is to help early stage companies mature and scale into companies ready for growth capital. The firm’s team has more than 50 years of venture experience, successful operating backgrounds, and actively helps successful entrepreneurs grow companies from inception through exit. Connect with defy at https://defy.vc/ and @defyvc.

SOURCE CRED

Funding to accelerate platform expansion into new applications in cell-to-cell interactions and tissue

STOCKHOLM, June 30, 2025 — Pixelgen Technologies today announced that it has been awarded grant and equity financing of EUR 12.5 M ($14.7 million) from the European Innovation Council (EIC) Accelerator, a funding initiative under the European Union’s Horizon Europe program designed to support highly innovative start-ups with disruptive technologies. Pixelgen will use the financing to expand the applications of its Pixelgen Proxiome Kit, launched earlier this year as the first kit and software for protein interactome analysis of single cells at high capacity.

“We’re thrilled to receive this highly competitive funding from the EIC,” said Pixelgen co-founder and CEO Simon Fredriksson. “The process was rigorous, and the award further reinforces the value of Pixelgen’s technology to increase our understanding of complex cellular and functional cell surface arrangements, which we believe will advance drug development and deepen our understanding of precision medicine. The response from leading researchers in industry and academia to our Proxiome Kit has been very enthusiastic, and this grant will help accelerate its expansion into new applications, including cell-to-cell interactions, communication, and FFPE tissues.”

The EIC selected 40 innovative start-ups and small-to-medium-sized enterprises out of 150 applicants in its latest evaluation round to receive funding. The companies were chosen for their “transformative technologies and strong commercial promise,” according to the EIC.  

The Pixelgen Proxiome Kit is the first in a new product line by Pixelgen offering researchers the highest resolution of single cell analyses by providing a new omics dimension (protein interactomics), for novel insights into disease mechanisms, drug response, biomarker discovery, and more, in cancer, hematology, immunology, and cell therapy research. It’s based on the company’s proprietary Proximity Network Assay, which delivers nanoscale spatial analysis of immune cell proteins at scale and was recently presented on BioRxiv.

Pixelgen is backed by leading investors, including Industrifonden, Sweden’s venture capital fund, and Navigare Ventures.

About Pixelgen Technologies
Pixelgen Technologies AB is on a mission to deliver biology at the highest resolution by understanding the molecular basis of cellular function with new tools and technologies that decipher the protein interactomics of single cells in unprecedented ways. The company’s patented Proximity Network Assay delivers nanoscale spatial analysis of immune cell proteins at ultra-high capacity and underpins the Pixelgen Proxiome Kit for precision medicine. A foundational technology, the Proximity Network Assay will power a portfolio of products for translational research to accelerate advances in immunology, hematology, and cell therapy. Pixelgen was founded in 2020 by a team of passionate, experienced innovators and entrepreneurs and is venture-backed.

Contacts

Corporate:
Annika Branting
[email protected]
+46 762-69 68 46

Media:
Susan Thomas
[email protected]
+1 (619) 540-9195

SOURCE Pixelgen Technologies

LONDON, June 30, 2025 — King Street Capital Management, L.P. (“King Street”), a leading global investment firm, today announced the final close of its European Real Estate Special Situations Fund II (“ESS II” or “the Fund”), hitting its hard cap of ~$950 million of capital commitments within 12 months.

ESS II targets situations where traditional capital has retrenched with the objective of accessing institutional-grade real estate at compelling valuations. The Fund will invest across core markets in Western Europe, focusing on high-quality assets that are temporarily mispriced due to market illiquidity rather than fundamentals. Leveraging King Street’s ability to invest across the capital structure, ESS II offers flexible, asset-specific capital solutions tailored to borrower needs, with a focus on unlocking value through capital structure solutions, repositioning, and hands-on asset management.

ESS II attracted a globally diversified investor base across North America, Europe, Asia, and the Middle East, with 50% of commitments coming from re-ups of the firm’s predecessor ESS vehicle and existing King Street real estate investors.

“The strong investor demand for ESS II reflects confidence in King Street’s ability to deliver innovative financing solutions in a market where transparency and liquidity remain scarce,” said Brian Higgins, Founder and Managing Partner of King Street. “Amid historic dislocation, we see a clear path to recovery and believe ESS II is well-positioned to capitalize on a generational opportunity in European real estate.”

“Our strategy focuses on the intersection of quality and complexity, providing capital solutions for trophy assets trading below intrinsic value due to market stress,” said Paul Brennan, Partner and Co-Head of Real Estate responsible for leading the European business at King Street. “As traditional lenders pull back and capital remains scarce, we’re able to deploy flexible capital and access landmark assets through proprietary, off-market channels.”

The closing of ESS II marks a significant milestone in the growth of King Street’s real estate platform. Recent investments including the Four Seasons Rome, the Bauer Hotel Venice, Room00, Arlington House St. James, and Bravo! Students, demonstrate the team’s conviction in structurally resilient sectors with long term secular growth.

About King Street Capital Management
King Street is a global alternative investment firm founded in 1995, managing over $29 billion in assets across public and private markets. The firm combines deep fundamental research with tactical trading expertise and differentiated sourcing capabilities to uncover dislocations and mispriced opportunities across asset classes and throughout the capital structure.

King Street Real Estate focuses on debt and equity investments in special situations and thematic platforms. Our special situations strategy identifies compelling risk-adjusted investment opportunities across the capital structure, in high-quality real estate assets in major markets. Our exclusive, thematic platforms are built around property sectors with compelling secular tailwinds. Since its inception, King Street has completed transactions totaling over $20 billion in real estate securities and real estate-related investments.

For more information, please visit www.kingstreet.com. Follow King Street Capital Management and King Street Capital Real Estate on LinkedIn.

Media Contacts
Prosek Partners
[email protected] 

Logo – https://mma.prnewswire.com/media/1834844/King_Street_Logo.jpg